Center-Authored Papers

Filters: Author is Hammer, Scott M  [Clear All Filters]
2017
Janes HE, Cohen KW, Frahm N, De Rosa SC, Sanchez B, Hural J, Magaret CA, Karuna S, Bentley C, Gottardo R et al..  2017.  Higher T cell responses induced by DNA/rAd5 HIV-1 preventive vaccine are associated with lower HIV-1 infection risk in an efficacy trial.. The Journal of infectious diseases.
2016
Hanscom B, Janes HE, Guarino PD, Huang Y, Brown ER, Chen YQ, Hammer SM, Gilbert PB, Donnell DJ.  2016.  Brief Report: Preventing HIV-1 Infection in Women Using Oral Preexposure Prophylaxis: A Meta-analysis of Current Evidence.. Journal of acquired immune deficiency syndromes (1999). 73(5):606-608. Abstract
Hanscom B, Janes HE, Guarino PD, Huang Y, Brown ER, Chen YQ, Hammer SM, Gilbert PB, Donnell DJ.  2016.  Preventing HIV-1 Infection in Women using Oral Pre-Exposure Prophylaxis: A Meta-analysis of Current Evidence.. Journal of acquired immune deficiency syndromes (1999). Abstract
2015
Walsh SR, Moodie Z, Fiore-Gartland AJ, Morgan C, Wilck MB, Hammer SM, Buchbinder SP, Kalams SA, Goepfert PA, Mulligan MJ et al..  2015.  Vaccination with heterologous HIV envelope sequences and heterologous adenovirus vectors increases T cell responses to conserved regions (HVTN 083).. The Journal of infectious diseases. Abstract
Dawson L, Garner S, Anude C, Ndebele P, Karuna S, Holt R, Broder G, Handibode J, Hammer SM, Sobieszczyk ME.  2015.  Testing the waters: Ethical considerations for including PrEP in a phase IIb HIV vaccine efficacy trial.. Clinical trials (London, England). Abstract
Huang Y, Follmann D, Nason M, Zhang L, Huang Y, Mehrotra DV, Moodie Z, Metch B, Janes H, Keefer MC et al..  2015.  Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials.. PloS one. 10(9):e0136626. Abstract
2014
Goepfert PA, Elizaga ML, Seaton K, Tomaras GD, Montefiori DC, Sato A, Hural J, De Rosa SC, Kalams SA, McElrath MJ et al..  2014.  Specificity and 6-Month Durability of Immune Responses Induced by DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-Like Particles.. The Journal of infectious diseases. Abstract
2013
Hammer SM, Sobieszczyk ME, Janes H, Karuna ST, Mulligan MJ, Grove D, Koblin BA, Buchbinder SP, Keefer MC, Tomaras GD et al..  2013.  Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine.. The New England journal of medicine. Abstract
Janes H, Gilbert P, Buchbinder S, Kublin J, Sobieszczyk ME, Hammer SM.  2013.  In Pursuit of an HIV Vaccine: Designing Efficacy Trials in the Context of Partially Effective Non-Vaccine Prevention Modalities.. AIDS research and human retroviruses. Abstract
2012
Gilbert PB, Grove D, Gabriel E, Huang Y, Gray G, Hammer SM, Buchbinder SP, Kublin J, Corey L, Self SG.  2012.  A Sequential Phase 2b Trial Design for Evaluating Vaccine Efficacy and Immune Correlates for Multiple HIV Vaccine Regimens. Statistical Communications in Infectious Diseases. 3(1)
2011
Gilbert PB, Berger JO, Stablein D, Becker S, Essex M, Hammer SM, Kim JH, Degruttola VG.  2011.  Statistical interpretation of the RV144 HIV vaccine efficacy trial in Thailand: a case study for statistical issues in efficacy trials.. The Journal of infectious diseases. 203(7):969-75. Abstract
Pine SO, Kublin JG, Hammer SM, Borgerding J, Huang Y, Casimiro DR, McElrath MJ.  2011.  Pre-existing adenovirus immunity modifies a complex mixed Th1 and Th2 cytokine response to an Ad5/HIV-1 vaccine candidate in humans.. PloS one. 6(4):e18526. Abstract
Nicholson O, Dicandilo F, Kublin J, Sun X, Quirk E, Miller M, Gray G, Pape J, Robertson MN, Mehrotra DV et al..  2011.  Safety and Immunogenicity of the MRKAd5 gag HIV Type 1 Vaccine in a Worldwide Phase 1 Study of Healthy Adults.. AIDS research and human retroviruses. 27(5):557-567. Abstract